PMID- 25170865
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20171116
IS  - 1423-0313 (Electronic)
IS  - 0031-7012 (Linking)
VI  - 93
IP  - 5-6
DP  - 2014
TI  - Paeonol attenuates advanced oxidation protein product-induced oxidative stress 
      injury in THP-1 macrophages.
PG  - 286-95
LID - 10.1159/000363577 [doi]
AB  - BACKGROUND: Paeonol (2'-hydroxy-4'-methoxyacetophenone) is thought to possess a 
      broad range of clinically curative effects that are likely mediated by its 
      anti-inflammatory and antioxidant activities. AIMS: To elucidate the efficacy of 
      paeonol's anti-inflammatory and antioxidant activities and the underlying 
      mechanism of paeonol in advanced oxidation protein product (AOPP) stimulation of 
      THP-1 macrophages. MATERIALS AND METHODS: After incubating cells with AOPP plus 
      paeonol, nitric oxide (NO) production and the levels of inducible NO synthase 
      (iNOS), receptor for advanced glycation end products (RAGE), CD36, scavenger 
      receptor (SR)-A, and SR-B1 were calculated. Moreover, THP-1 macrophages were 
      preincubated with paeonol, the free radical scavenger N-acetylcysteine (NAC), 
      NADPH oxidase inhibitors [apocynin, diphenylene iodonium (DPI)], and the specific 
      inhibitor of nuclear factor-kappaB pyrrolidine dithiocarbamate (PDTC) prior to 
      incubation with AOPP, and the levels of intracellular reactive oxygen species 
      (ROS) production and tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, 
      and monocyte chemotactic protein 1 (MCP-1) were determined. RESULTS: Paeonol 
      increased NO production and the mRNA level of iNOS, whereas it decreased ROS 
      production. ROS production was also effectively attenuated by apocynin, DPI, NAC, 
      and PDTC. Furthermore, these inhibitors and paeonol could downregulate the mRNA 
      and protein levels of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, and MCP-1). 
      Paeonol significantly reduced the expression levels of RAGE and CD36 but 
      increased the expression levels of SR-A and SR-B1. CONCLUSIONS: These results 
      indicate that paeonol can decrease proinflammatory cytokines in THP-1 
      macrophages, likely through RAGE-, CD36-, SR-A-, and SR-B1-mediated signals 
      involving NADPH oxidase-dependent ROS generation. This suggests that paeonol can 
      be used as a therapeutic agent for diseases contributing to oxidative stress 
      injury.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Ping, Mao
AU  - Ping M
AD  - Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, 
      PR China.
FAU - Xiao, Wei
AU  - Xiao W
FAU - Mo, Liqian
AU  - Mo L
FAU - Xiao, Xiaoyan
AU  - Xiao X
FAU - Song, Shaolian
AU  - Song S
FAU - Tang, Waijiao
AU  - Tang W
FAU - Yang, Xixiao
AU  - Yang X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140821
PL  - Switzerland
TA  - Pharmacology
JT  - Pharmacology
JID - 0152016
RN  - 0 (Acetophenones)
RN  - 0 (Advanced Oxidation Protein Products)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (CD36 Antigens)
RN  - 0 (Cytokines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (SCARB1 protein, human)
RN  - 0 (Scavenger Receptors, Class A)
RN  - 0 (Scavenger Receptors, Class B)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 3R834EPI82 (paeonol)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
SB  - IM
MH  - Acetophenones/*pharmacology
MH  - Advanced Oxidation Protein Products
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Antioxidants/*pharmacology
MH  - CD36 Antigens/genetics
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Cytokines/genetics
MH  - Humans
MH  - Macrophages/*drug effects/metabolism
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type II/genetics
MH  - Oxidative Stress/drug effects
MH  - RNA, Messenger/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/genetics
MH  - Scavenger Receptors, Class A/genetics
MH  - Scavenger Receptors, Class B/genetics
EDAT- 2014/08/30 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/08/30 06:00
PHST- 2013/12/06 00:00 [received]
PHST- 2014/05/13 00:00 [accepted]
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
AID - 000363577 [pii]
AID - 10.1159/000363577 [doi]
PST - ppublish
SO  - Pharmacology. 2014;93(5-6):286-95. doi: 10.1159/000363577. Epub 2014 Aug 21.